- AdventHealth Research Institute
Janisette Rivera-Rollins, a sixth-grade teacher and mother of two from Central Florida, never imagined that a clinical trial would change the course of her life. Diagnosed with triple-negative breast cancer (TNBC) in 2022 — a particularly aggressive and hard-to-treat form of the disease — she endured months of traditional chemotherapy, immunotherapy, surgery, and radiation. While those treatments shrank her tumor, they didn’t eliminate it. Then came a new opportunity: a clinical trial testing an investigational drug called datopotamab deruxtecan at AdventHealth Cancer Institute. After much prayer and with the support of her care team, Janisette enrolled — becoming the first Central Florida participant in this global study. Just five months later, on her 34th birthday, she was declared cancer-free.
Now being closely monitored by Dr. Wassim McHayleh and his team, Janisette’s story represents a promising future in cancer care. The drug she received belongs to a new class of therapies known as antibody-drug conjugates, which target cancer cells directly to maximize effectiveness while minimizing side effects. As the trial continues to enroll patients across the region, researchers hope this treatment may set a new standard for TNBC, a disease that disproportionately affects younger women and women of color. For Janisette — and the many patients who will follow — it’s more than a clinical advancement; it’s a second chance at life. Read the full story by clicking the button below.
Recent News
Under the leadership of principal investigator Michael Seidman, MD, AdventHealth Research Institute is participating in the multi-site Clinical Trial of Etanercept (TNF-alpha Blocker) for Treatment of...
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...
Dr. Kirk Erickson Joins the NavNeuro Podcast to Discuss the Connection Between Physical Activity and Brain Health
Results From IGNITE Research Study Published in the Medical Journal "Age and Ageing"
“We are at a pivotal point in our understanding of neuroscience and in particular, neuroplasticity – the ability of neural networks in the brain to change through growth and reorganization. This new...
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism, introduces a metagenomics-powered approach to accurately track dietary intake...
The AdventHealth Cancer Institute has been recognized in Becker's Hospital Review as one of the top 100 hospitals and health systems in the country for its excellence in oncology.
In this blog Dr. Amir Kachooei shares his view on AdventHealth's orthopedic research efforts and the future of orthopedic medicine.
Florida Trend for Breast Cancer Month features Dr. McHayleh and his clinical trial Tropion! A participant in the study was declared cancer-free after about 5 months of treatment.
Dr. Patricia Robinson has received has been named one of 50 Most Influential Clinical Executives in 2024 by Modern Healthcare.
Dr. Daryl Osbahr serves as team orthopedic surgeon and team physician for U.S. Men's National Soccer Team.
and helps the team hit health goals during summer events.
In a recent study, health complications dropped by 24 percent in those taking semaglutide, the active ingredient in Ozempic and Wegovy.